-
[show abstract]
[hide abstract]
ABSTRACT: Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present two cases of capillary-leak syndrome in patients with pancreatic cancer treated with gemcitabine.
Gastroentérologie Clinique et Biologique 01/2008; 31(12):1143-5. · 0.80 Impact Factor
-
Agnès Cournede,
Pauline Ries,
Karine Richard,
Alexandra Guillain,
Laëtitia Dahan,
Philippe Grandval,
Bertrand Pourroy,
Vincent Moutardier,
Jean Hardwigsen,
Diane Braguer,
Jean-François Seitz
[show abstract]
[hide abstract]
ABSTRACT: Liver metastases of colorectal cancer are rarely rapidly resectable. The efficacy of new chemotherapy regimen, in particular the combination of 5FU and oxaliplatin make further surgical resection possible in the case of an objective response in some patients. Three patients with metastatic colorectal cancer received oxaliplatin-based chemotherapy; only minimal and transient neurosensory toxicity occurred. After a partial response to treatment, surgical resection of metastases was performed. Patients reported major exacerbation of oxaliplatin-induced neurosensory toxicity following surgery (between day 7 and day 15). One patient experienced sensory loss of the extremities with functional impairment (grade 3 on Levi's scale). The symptoms persisted for 812 months after surgery in the three patients. Only seven similar cases have been reported. Toxicity could be associated with the concentration of oxaliplatin in the red blood cells: oxaliplatin binds irreversibly to erythrocytes. This exacerbation could be the consequence of peroperative hemolysis with a redistribution of the pool of intra-erythrocytic oxaliplatin biotransformation products into the plasma. We did not find any relationship with anesthesic or per-operative medications. Studies are necessary to define the precise mechanism and the frequency of this reaction.
Gastroentérologie Clinique et Biologique 05/2005; 29(4):461-4. · 0.80 Impact Factor
-
Agnès Cournede,
Pauline Ries,
Karine Richard,
Alexandra Guillain,
Laëtitia Dahan,
Philippe Grandval,
Bertrand Pourroy,
Vincent Moutardier,
Jean Hardwigsen,
Diane Braguer,
Jean-François Seitz
[show abstract]
[hide abstract]
ABSTRACT: Liver metastases of colorectal cancer are rarely rapidly resectable. The efficacy of new chemotherapy regimen, in particular the combination of 5FU and oxaliplatin make further surgical resection possible in the case of an objective response in some patients.Three patients with metastatic colorectal cancer received oxaliplatin-based chemotherapy; only minimal and transient neurosensory toxicity occured. After a partial response to treatment, surgical resection of metastases was performed. Patients reported major exacerbation of oxaliplatin-induced neurosensory toxicity following surgery (between day 7 and day 15). One patient experienced sensory loss of the extremities with functional impairment (grade 3 on Levi's scale). The symptoms persisted for 8-12 months after surgery in the three patients.Only seven similar cases have been reported. Toxicity could be associated with the concentration of oxaliplatin in the red blood cells: oxaliplatin binds irreversibly to erythrocytes. This exacerbation could be the consequence of peroperative hemolysis with a redistribution of the pool of intra-erythrocytic oxaliplatin biotransformation products into the plasma. We did not find any relationship with anesthesic or per-operative medications. Studies are necessary to define the precise mechanism and the frequency of this reaction.
Gastroentérologie Clinique et Biologique. 29(4):461-464.
-
[show abstract]
[hide abstract]
ABSTRACT: Pancreatic adenocarcinoma is the fifth most common cause of cancer-related mortality in the world. The nucleoside analogue gemcitabine is the established standard therapy for advanced disease. Rare cases of gemcitabine-associated systemic capillary leak syndrome have been reported. Here, we present two cases of capillary-leak syndrome in patients with pancreatic cancer treated with gemcitabine.
Gastroentérologie Clinique et Biologique. 31(12):1143-1145.
